Transcription factors and breast cancer

Endocrine-Related Cancer

Volumn 5, Issue 4, 1998, Pages 271-282

  Benz, C C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

BREAST CANCER; CHIMERA; COVALENT BOND; GENE REARRANGEMENT; GENETIC REGULATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

EID: 0032430302     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050271     Document Type: Review

References (85)

1. Amati B, Alevizopoulos K & Vlach J 1998 Myc and the cell cycle. Frontiers in Bioscience 3 d250-d268.
2. Antila E, Mussalo-Rauhamaa H, Kantola M, Atroshi F & Westermarck T 1996 Association of cadmium with human breast cancer. Science of the Total Environment 186 251-256.
3. Anzick AL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965-968.
4. Arnold SF, Obourn JD, Jaffe H & Notides AC 1994 Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Molecular Endocrinology 8 1208-1214.
5. Baylin SB, Herman JG, Graff JR, Vertino PM & Issa JP 1998 Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 72 142-196.
6. Benz CC 1995 Hormone-responsive tumors. In Endocrinology and Metabolism, edn 3, pp 1785-1811. Eds JD Baxter, P Felig & LA Frohman. New York: McGraw-Hill Inc.
7. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S & Thor A 1997 HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15 1513-1525.
8. Berlett BS & Stadtman ER 1997 Protein oxidation in aging, disease, and oxidative stress. Journal of Biological Chemistry 272 20313-20316.
9. Bertwistle D & Ashworth A 1998 Functions of the BRCA1 and BRCA2 genes. Current Opinion in Genetics and Development 8 14-20.
10. Bouchard C, Staller P & Eilers M 1998 Control of cell proliferation by Myc. Trends in Cell Biology 8 202-206.
11. Bunone G, Briand P-A, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
12. Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3 227-230.
13. Chen TK, Smith LM, Gebhardt DK Birrcr MJ & Brown PH 1996 Activation and inhibition of the AP-1 complex in human breast cancer cells. Molecular Carcinogenesis 15 215-226.
14. Crook T, Crossland S, Crompton MR, Osin P & Gusterson BA 1997 p53 mutations in BRCA1-associated familial breast cancer. Lancet 350 638-639.
15. Crooke ST 1996 The future of sequence-specific transcriptional inhibition. Cancer Investigation 14 89-90.
16. Darnell JE Jr 1997 STATs and gene regulation. Science 277 1630-1635.
17. DePinho RA 1998 The cancer-chromatin connection. Nature 391 533-536.
18. Dickson RB & Lippman ME 1987 Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Reviews 8 29-43.
19. Dowsett M, Daffada A, Chan CM & Johnston SR 1997 Oestrogen receptor mutants and variants in breast cancer. European Journal of Cancer 33 1177-1183.
20. Dumont JA, Bitoni AJ, Wallace CD, Baumann RJ, Cashman EA & Cross-Doersen DE 1996 Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth and Differentiation 7 351-359.
21. Enver T & Greaves M 1998 Loops, lineage, and leukemia. Cell 949-12.
22. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J & Callahan R 1986 Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proceedings of the National Academy of Sciences of the USA 83 4834-4838.
23. Faisst S & Meyer S 1992 Compilation of vertebrate-encoded transcription factors. Nucleic Acids Research 20 3-26.
24. Finkel T 1998 Oxygen radical and signaling. Current Opinion in Cell Biology 10 248-253.
25. Garcia R, Yu C-L, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP & Jove R 1997 Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth and Differentiation 8 1267-1276.
26. Garcia-Morales P, Saceda M, Kenney N, Kim N, Salomon DS, Gottardis MM, Solomon HB, Sholler PF, Jordan VC & Martin MB 1994 Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. Journal of Biological Chemistry 269 16896-16901.
27. Golub TR, Barker GF, Stegmaier K & Gilliland DG 1997 The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. In: Chromosomal Translocations and Oncogenic Transcription Factors, pp 67-79. Eds FJ Rauscher III & PK Vogt. Berlin: Springer-Verlag.
28. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW & Heyman RA 1996 Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Research 56 5566-5570.
29. Grimwade D & Solomon E 1997 Characterisation of the PML/ RARα rearrangement associated with t(15;17) acute promyelocytic leukemia. In Chromosomal Translocations and Oncogenic Transcription Factors, pp 81-112. Eds FJ Rauscher III & PK Vogt PK. Berlin: Springer-Verlag.
30. Hartmann A, Blaszyk H, Kovach JS & Sommer SS 1997 The molecular epidemiology of p53 gene mutations in human breast cancer. Trends in Genetics 13 27-33.
31. Hayashi S-I, Harjiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J & Tanaka H 1997 Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Research 25 4035-4040.
32. Helin K 1998 Regulation of cell proliferation by the E2F transcription factors. Current Opinion in Genetics and Development 8 28-35.
33. Hennighausen L, Robinson GW, Wagner K-U & Liu X 1997 Developing a mammary gland is a Stat affair. Journal of Mammary Gland Biology and Neoplasia 2 365-372.
34. Henriksson M & Lüscher B 1996 Proteins of the Myc network: essential regulators of cell growth and differentiation. Advances in Cancer Research 68 109-182.
35. Hopp TA & Fuqua SAW 1998 Estrogen receptor variants. Journal of Mammary Gland Biology and Neoplasia 3 73-83.
36. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS & Tung L 1996 Nuclear receptor coactivators and corepressors. Molecular Endocrinology 10 1167-1177.
37. Jackson WA, Richer RK, Bain DL, Takimoto GS, Ting L & Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology 11 693-705.
38. Johnston SRD, Lu B, Dowsett M, Liang X, Kaufman M, Scott GK, Osborne CK & Benz CC 1997 Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Research 57 3723-3727.
39. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landersberger N, Strouboulis J & Wolffe AP 1998 Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics 19 187-191.
40. Kallioniemi O-P & Visakorpi T 1996 Genetic basis and clonal evolution of human prostate cancer. Advances in Cancer Research 68 225-255.
41. Karin M 1995 The regulation of AP-1 activity by mitogen-activated protein kinases. Journal of Biological Chemistry 270 16483-16486.
42. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum B, Gaudray P & Theillet C 1994 Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes, Chromosomes and Cancer 9 42-48.
43. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H & Masushige S 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
44. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME & McInerney EM 1997 Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Research and Treatment 44 23-38.
45. Khan SA, Rogers MAM, Khurana KK, Meguid MM & Numann PJ 1998 Estrogen receptor expression in benign breast epithelium and breast cancer risk. Journal of the National Cancer Institute 90 37-42.
46. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D & Hong K 1996 Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Research 56 5522-5528.
47. Kuiper G & Gustafsson J-A 1997 The novel estrogen receptor-ß subtype: potential role in cell-and promoter-specific actions of estrogens and antiestrogens. FEBS Letters 410 87-90.
48. Lapidus RG, Nass SJ & Davidson NE 1998 The loss of estrogen and progesterone receptor gene expression in human breast cancer. Journal of Mammary Gland Biology and Neoplasia 3 85-94.
49. Latchman DS 1996 Transcription-factor mutations and disease. New England Journal of Medicine 334 28-33.
50. Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88 323-331.
51. Loeb LA 1998 Cancer cells exhibit a mutator phenotype. Advances in Cancer Research 72 25-56.
52. Look AT 1997 Oncogenic transcription factors in the human acute leukemias. Science 278 1059-1064.
53. Lu B, Johnsto SRD, Scott GK, Kushner P, McMillan A, Dowsett M & Benz CC 1997 Increased Jun N-terminal kinase (JNK) and AP-1 DNA binding activities in human breast tumors with acquired tamoxifen resistance. Breast Cancer Research and Treatment 6 345.
54. May WA & Denny CT 1997 Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. In Chromosomal Translocations and Oncogenic Transcription Factors, pp 143-149. Eds FJ Rauscher III & PK Vogt. Berlin: Springer-Verlag.
55. Mittnacht S 1998 Control of pRb phosphorylation. Current Opinion in Genetics and Development 8 21-27.
56. Montgomery PA, Scott GK, Luce MC, Kaufmann M & Benz CC 1993 Human breast tumors containing non-DNA binding immunoreactive (67 kDa) estrogen receptor. Breast Cancer Research and Treatment 26 181-189.
57. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN & Bird A 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 28 386-389.
58. Neidle S 1994 Principles in the design of DNA-interactive molecules. In New Approaches in Cancer Pharmacology: Drug Design and Development, vol. II, pp 11-22. Ed P Workman. Heidelberg: Springer-Verlag.
59. Noonberg SB, Scott GK, Hunt CA, Hogan ME & Benz CC 1994 Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodcoxyribonucleotides. Gene 149 123-126.
60. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERß at AP-I sites. Science 277 1508-1510.
61. Patel U, Grundfest-Broniatowski S, Gupta M & Banerjee S 1994 Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene 9 3695-3700.
62. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3 222-226.
63. Rabbitts TH 1994 Chromosomal translocations in human cancer. Nature 372 143-149.
64. Rao GN, Ney E & Herbert RA 1998 Effect of retinoid analogues on mammary cancer in transgenic mice with c-ncu breast cancer oncogene. Breast Cancer Research and Treatment 48 265-271.
65. Rauscher III FJ & Vogt PK 1997 Chromosomal Translocations and Oncogenic Transcription Factors, pp 1-166. Berlin: Springer-Verlag.
66. Russo IH & Russo J 1998 Role of hormones in mammary cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia 349-61.
67. Sanchez I & Dynlacht BD 1996 Transcriptional control of the cell cycle. Current Opinion in Cell Biology 8 318-324.
68. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, Cornelisse CJ, van de Vijver MJ & Mooi WJ 1992 Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Research 52 5229-5234.
69. Scott GK, Kushner P, Vigne JL & Benz CC 1991 Truncated forms of DNA-binding estrogen receptors in human breast cancer. Journal of Clinical Investigation 88 700-706.
70. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 656-666.
71. Sun Y & Oberley LW 1996 Redox regulation of transcriptional activators. Free Radical Biology and Medicine 21 335-348.
72. Sutherland RL, Prall OWJ, Watts CKW & Musgrove EA 1998 Estrogen and progestin regulation of cell cycle progression. Journal of Mammary Gland Biology and Neoplasia 3 63-72.
73. Treisman R 1996 Regulation of transcription by MAP kinase cascades. Current Opinion in Cell Biology 8 205-215.
74. Tripathy D & Benz CC 1993 Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. In Oncogenes and Tumor Suppressor Genes in Human Malignancies, pp 15-60. Eds CC Benz & E Liu. Boston: Kluwer Academic Publishers.
75. Tripathy D & Benz CC 1994 Growth factors and their receptors. Hematology-Oncology Clinics of North America 8 29-50.
76. Turkson J, Bowmȧn T, Garcia R, Caldenhoven E, De Groot RP & Jove R 1998 Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Molecular and Cellular Biology 18 2545-2552.
77. Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, T'Ang A, Fung YK, Brammer WJ & Walker RA 1989 The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 4 725-729.
78. Walker RA, Jones JL, Chappell S, Walsh T & Shaw JA 1997 Molecular pathology of breast cancer and its application to clinical management. Cancer and Metastasis Reviews 165-27.
79. Wang G, Seidman MM & Glazer PM 1996 Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271 802-805.
80. Wasylyk B & Nordheim A 1997 Ets transcription factors: partners in the integration of signal responses. In Transcription Factors in Eukaryotes. pp 253-286. Ed AG Papavassiliou. Heidelberg: Springer-Verlag.
81. Webb P, Lopez GN, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443-456.
82. Weigel N 1996 Steroid hormone receptors and their regulation by phosphorylation. Biochemical Journal 319 657-667.
83. Welch JJ, Rauscher III FJ & Beerman TA 1994 Targeting DNA-binding drugs to sequence-specific transcription factor-DNA complexes. Journal of Biological Chemistry 49 31051-31058.
84. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z & de Thé H1997 Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 94 3978-3983.
85. Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J, Bernards R & Michalides RJ 1997 CDK-independent activation of estrogen receptor by cyclin D1. Cell 88 405-415.